Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Current Assets for 2 consecutive years, with $160.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Assets fell 45.69% to $160.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $160.4 million, a 45.69% decrease, with the full-year FY2024 number at $160.4 million, down 45.69% from a year prior.
  • Current Assets was $160.4 million for Q4 2024 at Inhibrx Biosciences, down from $242.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $295.4 million in Q4 2023 to a low of $160.4 million in Q4 2024.